TY - JOUR
T1 - Second-line therapies in immune thrombocytopenia
AU - Grace, Rachael F.
AU - Neunert, Cindy
PY - 2016
Y1 - 2016
N2 - Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding. Although many children and adults with ITP will not need therapy beyond historic first-line treatments of observation, steroids, intravenous immunoglobulin (IVIG), and anti-D globulin, others will have an indication for second-line treatment. Selecting a second-line therapy depends on the reason for treatment, which can vary from bleeding to implications for health-related quality of life (HRQoL) to likelihood of remission and patient preference with regard to adverse effects, route of administration, and cost. Published studies of these treatments are limited by lack of comparative trials, in addition to inconsistent outcome measures, definitions, and efficacy endpoints. This article provides an up-to-date comparison of the second-line treatments, highlighting important outcome measures including bleeding, HRQoL, fatigue, and platelet counts, which influence treatment selection in a shared decision-making model.
AB - Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding. Although many children and adults with ITP will not need therapy beyond historic first-line treatments of observation, steroids, intravenous immunoglobulin (IVIG), and anti-D globulin, others will have an indication for second-line treatment. Selecting a second-line therapy depends on the reason for treatment, which can vary from bleeding to implications for health-related quality of life (HRQoL) to likelihood of remission and patient preference with regard to adverse effects, route of administration, and cost. Published studies of these treatments are limited by lack of comparative trials, in addition to inconsistent outcome measures, definitions, and efficacy endpoints. This article provides an up-to-date comparison of the second-line treatments, highlighting important outcome measures including bleeding, HRQoL, fatigue, and platelet counts, which influence treatment selection in a shared decision-making model.
UR - http://www.scopus.com/inward/record.url?scp=85020304742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020304742&partnerID=8YFLogxK
U2 - 10.1182/asheducation-2016.1.698
DO - 10.1182/asheducation-2016.1.698
M3 - Article
C2 - 27913549
AN - SCOPUS:85020304742
SN - 1520-4391
VL - 2016
SP - 698
EP - 706
JO - Hematology
JF - Hematology
IS - 1
ER -